

Pharmacotherapeutic report on mometasonfuroate (Asmanex®) for the indication 'persistent asthma'

Medicine Mometasonfuroate 200 or 400 microgram inhalation powder.

Summary of the therapeutic value

Favourable effects. Based on direct comparative studies, mometasonfuroate, used at the recommended dose, has the same effect on lung function parameters as the recommended doses of budesonide, beclometason and fluticason in patients with moderate to severe persistent asthma. Based on placebo-controlled studies, the comparative effect could be extrapolated to patients with mild persistent asthma who only use short-acting bronchodilators.

Unfavourable effects. The side effects profile of mometasonfuroate is the same as that of the inhalation corticosteroids budesonide, beclometason and fluticason.

Experience. Sufficient experience has been obtained with mometasonfuroate; ample experience has been obtained with budesonide, beclometason and fluticason.

Applicability. The applicability of mometasonfuroate, budesonide, beclometason and fluticason is almost identical. Unlike budesonide, beclometason and fluticason, it is possible to use mometasonfuroate on children up to the age of 12 years.

Ease of use. Mometason and the comparative treatments budesonide, beclometason and fluticason are administered via inhalation. The ease with which mometasonfuroate can be used is comparable with that of the other inhalation corticosteroids.

final conclusion. For the treatment of persistent asthma, mometasonfuroate has a similar therapeutic value to that of budesonide, beclometason and fluticason.

*The original text of the summary of this **CFH-report** was in Dutch. Although great care was taken in translating the text from Dutch to English, the translation may nevertheless have resulted in discrepancies. Rights may only be derived on the basis of the Dutch version of the summary of the CFH-report.*

Furthermore, CVZ points out that only the summary of this report was translated. A proper understanding of all relevant considerations and facts would require familiarity with the Dutch version of this report, including all appendices.